Silexion Therapeutics Corp (SLXN)

Currency in USD
0.165
+0.011(+7.15%)
Closed·
0.1650.000(0.00%)
·
SLXN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.1600.171
52 wk Range
0.14235.600
Key Statistics
Prev. Close
0.165
Open
0.171
Day's Range
0.16-0.171
52 wk Range
0.142-35.6
Volume
289.19K
Average Volume (3m)
9.97M
1-Year Change
-99.5045%
Book Value / Share
0.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SLXN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.000
Upside
+2,930.30%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Silexion Therapeutics Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Neutral

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.000
(+2,930.30% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Hold---DowngradeJul 29, 2026
Litchfield Hills Research
Buy6.00+3,536.36%-New CoverageDec 15, 2025

Earnings

Latest Release
Aug 14, 2026
EPS / Forecast
-5.17 / -13.10
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SLXN Income Statement

Compare SLXN to Peers and Sector

Metrics to compare
SLXN
Peers
Sector
Relationship
P/E Ratio
−0.1x−1.1x−0.3x
PEG Ratio
-0.000.00
Price/Book
20.9x0.0x2.6x
Price / LTM Sales
-3.8x2.9x
Upside (Analyst Target)
-1,275.0%62.9%
Fair Value Upside
Unlock13.6%8.1%Unlock

Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
33.90K0.61%5.19K
Public Companies & Retail Investors
5.53M99.39%845.52K
Total
5.56M100.00%850.71K

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Hudson River Trading LLC0.27%15,2392
Lincoln Alternative Strategies Llc0.24%13,1252

People Also Watch

2.98
GLND
-3.87%
0.9260
RETO
+4.04%
6.19
GRML
-0.16%
3.980
VEEA
-1.00%
0.8852
BENF
-9.57%

FAQ

What Is the Silexion Therapeutics (SLXN) Stock Price Today?

The Silexion Therapeutics stock price today is 0.165 USD.

What Stock Exchange Does Silexion Therapeutics Trade On?

Silexion Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Silexion Therapeutics?

The stock symbol for Silexion Therapeutics is "SLXN."

What Is the Silexion Therapeutics Market Cap?

As of today, Silexion Therapeutics market cap is 917.440K USD.

What Is Silexion Therapeutics's Earnings Per Share (TTM)?

The Silexion Therapeutics EPS (TTM) is -38.75.

When Is the Next Silexion Therapeutics Earnings Date?

Silexion Therapeutics will release its next earnings report on Nov 18, 2026.

From a Technical Analysis Perspective, Is SLXN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Silexion Therapeutics Stock Split?

Silexion Therapeutics has split 3 times.

How Many Employees Does Silexion Therapeutics Have?

Silexion Therapeutics has 14 employees.

What is the current trading status of Silexion Therapeutics (SLXN)?

As of Oct 22, 2026, Silexion Therapeutics (SLXN) is trading at a price of 0.165 USD, with a previous close of 0.165 USD. The stock has fluctuated within a day range of 0.160 USD to 0.171 USD, while its 52-week range spans from 0.142 USD to 35.600 USD.

What Is Silexion Therapeutics (SLXN) Price Target According to Analysts?

The average 12-month price target for Silexion Therapeutics is 5.000 USD, with a high estimate of 5 USD and a low estimate of 5 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +2,930.30% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.